相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Candida auris: The recent emergence of a multidrug-resistant fungal pathogen
Kaitlin Forsberg et al.
MEDICAL MYCOLOGY (2019)
Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis
Neil R. H. Stone et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Broad antifungal resistance mediated by RNAi-dependent epimutation in the basal human fungal pathogen Mucor circinelloides
Zanetta Chang et al.
PLOS GENETICS (2019)
Candida auris: An emerging pathogen incognito?
Jeniel E. Nett
PLOS PATHOGENS (2019)
MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis
Andrej Spec et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Candida auris exhibits resilient biofilm characteristics in vitro: implications for environmental persistence
B. Short et al.
JOURNAL OF HOSPITAL INFECTION (2019)
From the environment to the host: How non-azole agrochemical exposure affects the antifungal susceptibility and virulence of Cryptococcus gattii
Rafael Wesley Bastos et al.
SCIENCE OF THE TOTAL ENVIRONMENT (2019)
Dectin-2-Targeted Antifungal Liposomes Exhibit Enhanced Efficacy
Suresh Ambati et al.
MSPHERE (2019)
Voriconazole Resistance and Mortality in Invasive Aspergillosis: A Multicenter Retrospective Cohort Study
Pieter P. Lestrade et al.
CLINICAL INFECTIOUS DISEASES (2019)
Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance
William Hope et al.
MBIO (2019)
Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy
Lynn Miesel et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2019)
Fungal Infections with Ibrutinib and Other Small-Molecule Kinase Inhibitors
Marissa A. Zarakas et al.
CURRENT FUNGAL INFECTION REPORTS (2019)
The Candida auris Alert: Facts and Perspectives
Frederic Lamoth et al.
JOURNAL OF INFECTIOUS DISEASES (2018)
A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis
Stephen R. Brand et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2018)
Roles of Three Cryptococcus neoformans and Cryptococcus gattii Efflux Pump-Coding Genes in Response to Drug Treatment
Miwha Chang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
In Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris
Christopher L. Hager et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
The Novel Fungal Cyp51 Inhibitor VT-1598 Is Efficacious in Experimental Models of Central Nervous System Coccidioidomycosis Caused by Coccidioides posadasii and Coccidioides immitis
Nathan P. Wiederhold et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis-A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial
John E. Edwards et al.
CLINICAL INFECTIOUS DISEASES (2018)
A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009-17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance
Anuradha Chowdhary et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model
Christopher L. Hager et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Flucytosine resistance in Cryptococcus gattii is indirectly mediated by the FCY2-FCY1-FUR1 pathway
Kiem Vu et al.
MEDICAL MYCOLOGY (2018)
A systematic review of fluconazole resistance in clinical isolates of Cryptococcus species
Felix Bongomin et al.
MYCOSES (2018)
Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa
S. F. Molloy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Antifungal tolerance is a subpopulation effect distinct from resistance and is associated with persistent candidemia
Alexander Rosenberg et al.
NATURE COMMUNICATIONS (2018)
Limited ERG11 Mutations Identified in Isolates of Candida au ris Directly Contribute to Reduced Azole Susceptibility
Kelley R. Healey et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Emerging Fungal Pathogen Candida auris Evades Neutrophil Attack
Chad J. Johnson et al.
MBIO (2018)
The comparative efficacy of antiseptics against Candida auris biofilms
Ryan Kean et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
A Candida auris Outbreak and Its Control in an Intensive Care Setting
David W. Eyre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Candida auris in Healthcare Facilities, New York, USA, 2013-2017
Eleanor Adams et al.
EMERGING INFECTIOUS DISEASES (2018)
Investigation of the First Seven Reported Cases of Candida auris, a Globally Emerging Invasive, Multidrug-Resistant FungusUnited States, May 2013-August 2016 (Reprinted from vol 65, pg 1234-1237, 2016)
S. Vallabhaneni et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2017)
Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults
Taylor Sandison et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses
Shawn R. Lockhart et al.
CLINICAL INFECTIOUS DISEASES (2017)
Trehalose pathway as an antifungal target
John R. Perfect et al.
VIRULENCE (2017)
Calcineurin in fungal virulence and drug resistance: Prospects for harnessing targeted inhibition of calcineurin for an antifungal therapeutic approach
Praveen R. Juvvadi et al.
VIRULENCE (2017)
Candida auris: An emerging multidrug-resistant pathogen
David Sears et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2017)
Serum levels, safety and tolerability of new formulation SUBA-itraconazole prophylaxis in patients with haematological malignancy or undergoing allogeneic stem cell transplantation
Julian Lindsay et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Establishment and Use of Epidemiological Cutoff Values for Molds and Yeasts by Use of the Clinical and Laboratory Standards Institute M57 Standard
Shawn R. Lockhart et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2017)
Survival, Persistence, and Isolation of the Emerging Multidrug-Resistant Pathogenic Yeast Candida auris on a Plastic Health Care Surface
Rory M. Welsh et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2017)
The antifungal pipeline: a reality check
John R. Perfect
NATURE REVIEWS DRUG DISCOVERY (2017)
Microevolution of Serial Clinical Isolates of Cryptococcus neoformans var. grubii and C. gattii
Yuan Chen et al.
MBIO (2017)
Fluconazole-Induced Ploidy Change in Cryptococcus neoformans Results from the Uncoupling of Cell Growth and Nuclear Division
Sophie Altamirano et al.
MSPHERE (2017)
The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation
Emily Larkin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Biofilm-Forming Capability of Highly Virulent, Multidrug-Resistant Candida auris
Leighann Sherry et al.
EMERGING INFECTIOUS DISEASES (2017)
Azole Resistance in Aspergillus fumigatus: Can We Retain the Clinical Use of Mold-Active Antifungal Azoles?
Paul E. Verweij et al.
CLINICAL INFECTIOUS DISEASES (2016)
Pan Assay Interference Compounds (PAINS) and Other Promiscuous Compounds in Antifungal Research
Martin Pouliot et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
The Investigational Drug VT-1129 Is a Highly Potent Inhibitor of Cryptococcus Species CYP51 but Only Weakly Inhibits the Human Enzyme
Andrew G. S. Warrilow et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
Thomas F. Patterson et al.
CLINICAL INFECTIOUS DISEASES (2016)
F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase
Jason D. Oliver et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Emerging Threats in Antifungal-Resistant Fungal Pathogens
Dominique Sanglard
FRONTIERS IN MEDICINE (2016)
Combination Antifungal Therapy for Invasive Aspergillosis A Randomized Trial
Kieren A. Marr et al.
ANNALS OF INTERNAL MEDICINE (2015)
Echinocandin Resistance in Candida
David S. Perlin
CLINICAL INFECTIOUS DISEASES (2015)
Identification of a New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids
Visesato Mor et al.
MBIO (2015)
Genotypic Diversity Is Associated with Clinical Outcome and Phenotype in Cryptococcal Meningitis across Southern Africa
Mathew A. Beale et al.
PLOS NEGLECTED TROPICAL DISEASES (2015)
Epidemiology and Risk Factors for Echinocandin Nonsusceptible Candida glabrata Bloodstream Infections: Data From a Large Multisite Population-Based Candidemia Surveillance Program, 2008-2014
Snigdha Vallabhaneni et al.
OPEN FORUM INFECTIOUS DISEASES (2015)
Mechanisms of Antifungal Drug Resistance
Leah E. Cowen et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2015)
Susceptibility and Diversity in the Therapy-Refractory Genus Scedosporium
M. Lackner et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Design and optimization of highly-selective fungal CYP51 inhibitors
William J. Hoekstra et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
Cryptococcus gattii Infections
Sharon C. -A. Chen et al.
CLINICAL MICROBIOLOGY REVIEWS (2014)
Multidrug-resistant endemic clonal strain of Candida auris in India
A. Chowdhary et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2014)
Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis
Anil A. Panackal et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2014)
Antifungal drug resistance evoked via RNAi-dependent epimutations
Silvia Calo et al.
NATURE (2014)
Epidemiology and risk factors for invasive candidiasis
Nur Yapar
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2014)
Candida auris-Associated Candidemia, South Africa
Rindidzani E. Magobo et al.
EMERGING INFECTIOUS DISEASES (2014)
Azole Heteroresistance in Cryptococcus neoformans: Emergence of Resistant Clones with Chromosomal Disomy in the Mouse Brain during Fluconazole Treatment
Edward Sionov et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Aspergillosis due to Voriconazole Highly Resistant Aspergillus fumigatus and Recovery of Genetically Related Resistant Isolates From Domiciles
Jan W. M. van der Linden et al.
CLINICAL INFECTIOUS DISEASES (2013)
Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations
Barbara D. Alexander et al.
CLINICAL INFECTIOUS DISEASES (2013)
Clinical-scale generation of multi-specific anti-fungal T cells targeting Candida, Aspergillus and mucormycetes
Lars Tramsen et al.
CYTOTHERAPY (2013)
Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST)
Michael A. Pfaller et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Combination Antifungal Therapy for Cryptococcal Meningitis
Jeremy N. Day et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
New Clonal Strain of Candida auris, Delhi, India
Anuradha Chowdhary et al.
EMERGING INFECTIOUS DISEASES (2013)
Identification of a Cryptococcus neoformans Cytochrome P450 Lanosterol 14α-Demethylase (Erg11) Residue Critical for Differential Susceptibility between Fluconazole/Voriconazole and Itraconazole/Posaconazole
Edward Sionov et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Fks1 and Fks2 Are Functionally Redundant but Differentially Regulated in Candida glabrata: Implications for Echinocandin Resistance
Santosh K. Katiyar et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial
Brad Spellberg et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Toward Developing a Universal Treatment for Fungal Disease Using Radioimmunotherapy Targeting Common Fungal Antigens
R. A. Bryan et al.
MYCOPATHOLOGIA (2012)
Efficacy of Oral E1210, a New Broad-Spectrum Antifungal with a Novel Mechanism of Action, in Murine Models of Candidiasis, Aspergillosis, and Fusariosis
Katsura Hata et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
In Vitro Activity of E1210, a Novel Antifungal, against Clinically Important Yeasts and Molds
Mamiko Miyazaki et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
New Fks Hot Spot for Acquired Echinocandin Resistance in Saccharomyces cerevisiae and Its Contribution to Intrinsic Resistance of Scedosporium Species
Michael E. Johnson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Current perspectives on echinocandin class drugs
David S. Perlin
FUTURE MICROBIOLOGY (2011)
Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009)
Michael A. Pfaller et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2011)
Structures of Cryptococcus neoformans Protein Farnesyltransferase Reveal Strategies for Developing Inhibitors That Target Fungal Pathogens
Michael A. Hast et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Photodynamic Therapy with Pc 4 Induces Apoptosis of Candida albicans
Minh Lam et al.
PHOTOCHEMISTRY AND PHOTOBIOLOGY (2011)
Deletion of Cryptococcus neoformans AIF Ortholog Promotes Chromosome Aneuploidy and Fluconazole-Resistance in a Metacaspase-Independent Manner
Camile P. Semighini et al.
PLOS PATHOGENS (2011)
Combination Flucytosine and High-Dose Fluconazole Compared with Fluconazole Monotherapy for the Treatment of Cryptococcal Meningitis: A Randomized Trial in Malawi
Jesse C. Nussbaum et al.
CLINICAL INFECTIOUS DISEASES (2010)
Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America
John R. Perfect et al.
CLINICAL INFECTIOUS DISEASES (2010)
Uptake of T-2307, a novel arylamidine, in Candida albicans
Hiroshi Nishikawa et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Cryptococcus neoformans Overcomes Stress of Azole Drugs by Formation of Disomy in Specific Multiple Chromosomes
Edward Sionov et al.
PLOS PATHOGENS (2010)
Use of Antifungal Combination Therapy: Agents, Order, and Timing
Melissa D. Johnson et al.
CURRENT FUNGAL INFECTION REPORTS (2010)
Heteroresistance to Fluconazole in Cryptococcus neoformans Is Intrinsic and Associated with Virulence
Edward Sionov et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Role for Fks1 in the Intrinsic Echinocandin Resistance of Fusarium solani as Evidenced by Hybrid Expression in Saccharomyces cerevisiae
Santosh K. Katiyar et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3-β-D-Glucan Synthase: Implication for the Existing Susceptibility Breakpoint
Guillermo Garcia-Effron et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?
Paul E. Verweij et al.
LANCET INFECTIOUS DISEASES (2009)
Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease
Leah E. Cowen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
In vitro and in vivo antifungal activities of T-2307, a novel arylamidine
Junichi Mitsuyama et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes
Andres Pascual et al.
CLINICAL INFECTIOUS DISEASES (2008)
Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis
Caitlin Reed et al.
CLINICAL INFECTIOUS DISEASES (2008)
Resistance to antifungal agents: Mechanisms and clinical impact
Zeina A. Kanafani et al.
CLINICAL INFECTIOUS DISEASES (2008)
Emergence of Azole Resistance in Aspergillus fumigatus and Spread of a Single Resistance Mechanism
Eveline Snelders et al.
PLOS MEDICINE (2008)
Immune reconstitution syndrome associated with opportunistic mycoses
Nina Singh et al.
LANCET INFECTIOUS DISEASES (2007)
Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients
Steve Trifilio et al.
CANCER (2007)
Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: The role of fluconazole resistance and immune reconstitution
Tihana Bicanic et al.
CLINICAL INFECTIOUS DISEASES (2006)
Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study
Kevin W. Garey et al.
CLINICAL INFECTIOUS DISEASES (2006)
Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis
E Dannaoui et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis
J Pachl et al.
CLINICAL INFECTIOUS DISEASES (2006)
Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak
JA Fraser et al.
NATURE (2005)
Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained:: a potential risk factor for hospital mortality
M Morrell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Management of central venous catheters in patients with cancer and candidemia
I Raad et al.
CLINICAL INFECTIOUS DISEASES (2004)
Infections due to emerging and uncommon medically important fungal pathogens
TJ Walsh et al.
CLINICAL MICROBIOLOGY AND INFECTION (2004)
Combination antifungal therapy
MD Johnson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial
AE Brouwer et al.
LANCET (2004)
A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects
JH Rex et al.
CLINICAL INFECTIOUS DISEASES (2003)
G484S amino acid substitution in lanosterol 14-alpha demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate
L Rodero et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Characterization of heteroresistance to fluconazole among clinical isolates of Cryptococcus neoformans
T Yamazumi et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2003)
Comparison of caspofungin and amphotericin B for invasive candidiasis.
J Mora-Duarte et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis
G Delmas et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Antifungal susceptibility of Candida biofilms:: Unique efficacy of amphotericin B lipid formulations and echinocandins
DM Kuhn et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Correlation of fluconazole MICs with clinical outcome in Cryptococcal infection
AI Aller et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
分享论文
